Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma

Published:2013-05-07 Issue:12 Volume:54 Page:2631-2638
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Dabaja Bouthaina S.,Phan Jack,Mawlawi Osama,Medeiros L. Jeffrey,Etzel Carol,Liang Fu-Wen,Podoloff Donald,Oki Yasuhiro,Hagemeister Fredrick B.,Chuang Hubert,Fayad Luis E.,Westin Jason Robert,Shihadeh Ferial,Allen Pamela K.,Wogan Christine F.,Rodriguez Maria A.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.784967

Reference30 articles.

1. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

2. Current trends in large cell lymphoma

3. Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma

4. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

5. Outcomes and Effect of Radiotherapy in Patients With Stage I or II Diffuse Large B-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Analysis

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of CT‑based radiomics model of PET-negative residual CT masses: a potential biomarker for predicting relapse‑free survival in non-Hodgkin lymphoma patients showing complete metabolic response;Abdominal Radiology;2023-10-27

2. Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study;HemaSphere;2023-07

3. Modern PET-Guided Radiotherapy Planning and Treatment for Malignant Lymphoma;Seminars in Nuclear Medicine;2023-05

4. Balancing the Therapeutic Ratio in DLBCL Requires Appropriate, Individualized Patient Selection Rather Than Broad Elimination of Radiation Therapy;International Journal of Radiation Oncology*Biology*Physics;2022-07

5. The Role of 18FDG-PET/CT in Malignant Lymphomas Clinical Implications;Artificial Intelligence in PET/CT Oncologic Imaging;2022